Stock Code：1762

Chunghwa Chemical Synthesis & Biotech Co., Ltd.

CCSB

Second Quarter 2024 Investor Conference

August 29, 2024



Safe Harbor Notice

- CCSB’ s presentation contains forward-looking statements subject to significant risks and uncertainties. Actual results may differ materially from those contained in the forward-looking statements.
- The forward-looking statements in this release reflect the current belief of CCSB as of the date of this release, we undertake no obligation to update these forward-looking statements for new information, future events or otherwise.

Company


- **Stock Code:1762**
- **Employee:321 (As of 2024/06/30)**
- **2024 /1/1-6/30 Revenue 0.7 billion**

- **Brief History**
- **Founded in 1964**
  - ✓ First registered and one of the largest bulk pharmaceutical chemical manufacturers in Taiwan
  - ✓ First FDA approved plant (1984) in Taiwan
- **Turning Points**
  - ✓ Formed the New Management Team in 1997, 4 cGMP Plants for Synthetic Products and 2 cGMP Plants for Biotechnology Products
  - ✓ Established US Sales Office- Pharmaports in 2000
  - ✓ Initial public offering on December 20, 2010

Key Strengths

- An API factory with bio-fermentation and chemical synthesis technology and equipment.
- Ensure compliance with and successfully pass inspections by the US FDA and European PIC/S regulations.
- Certified API master file DMFs for a variety of products, Export products are competitive.
- From small batch research and development to mass production of APIs, offering comprehensive one-stop services.

US DMF List



8625 • DEXBROMPHENIRAMINE MALEATE	13080 • METHOCARBAMOL USP	14234 • GUAIFENESIN USP	14235 • PRAVASTATIN SODIUM USP	17399 • RAPAMYCIN	17573 • TRANDOLAPRIL USP
18494 • MYCOPHENOLATE MOFETIL USP	18985 • TACROLIMUS	23213 • TACROLIMUS SD20	24372 • MYCOPHENOLATE MOFETIL HYDROCHLORIDE ANHYDROUS	26271 • ETHYL ICOSAPENTATE	26819 • EVEROLIMUS PRE-MIX USP
27216 • EVEROLIMUS USP	27585 • CASPOFUNGIN ACETATE	31189 • RAPAMYCIN (SIROLIMUS)	31276 • CARFILZOMIB	33333 • MYCOPHENOLATE MOFETIL USP (PROCESS B)	35848 • MYCOPHENOLATE SODIUM USP
35849 • FAVIPIRAVIR	36030 • BARICITINIB	36174 • RIBOCICLIB SUCCINATE	36640 • MIDOSTAURIN	37532 • TOFACITINIB CITRATE	37586 • PALBOCICLIB
37597 • OZANIMOD HYDROCHLORIDE	38111 • EVEROLIMUS B02 USP	38310 • TACROLIMUS (PROCESS B)	38511 • DIFELIKEFALIN ACETATE	39312 • ESLICARBAZEPINE ACETATE	

Key Products

- Active Pharmaceutical Ingredients (API) for brand drugs and generic drugs
  - Tacrolimus：As an immunosuppressant API, it is used to prevent organ transplant rejection.
  - Everolimus：It is used for anticancer drug, cardiovascular stent coating and immunosuppressive dosages.
  - Ethyl Icosapentate：For triglyceride lowering medication.
  - Caspofugin Acetate: An echinocandin antifungal drug.

Consolidated Comprehensive Income Statement

Amount: NT$ Thousand


Year / Item	2024/4/1-6/30		2024/1/1-6/30	
	Amount	%	Amount	%
Net Sales	$461,158	100%	$712,870	100%
Gross Profit	117,701	25%	234,997	33%
Operating Profit	23,444	5%	37,774	5%
Profit before Tax	30,033	6%	75,997	10%
Net Profit	$21,077	4%	$61,632	8%
Basic EPS(NT$)	$0.27		$0.79	

2024/01/01-06/30 Sales Distribution By Region


Region/ Product	%	EPAE	EVE	FK506	MMF	RAPA	CAS
US	35%	●	●		●	●	
Asia	24%		●	●	●	●	
Europe	29%		●			●	●
Taiwan	12%			●			

Share of Revenue by Key Products

2024/1/1-6/30



2023/1/1-6/30



Latest News

Capacity

- Invested in new equipment to enhance the product competitiveness of Caspofungin and Everolimus.
- Procure the necessary equipment for producing semi-recombinant Semaglutide.


Regulatory

- Accomplished authorities inspections from Germany , US and Japan.

ESG

- Continue providing care for the elderly in the community this year , while continuing to implement ESG social care initiatives.

Future Outlook (1/2)



- Process optimization, strain improvement and capacity increase of key products Everolimus, Tacrolimus and Caspofungin , which will further boost market penetration and share.
- Registration approvals and regulatory change operations are conducted in multiple countries, with the goal of continuously expanding into new markets.
- Short term increase of revenue from CDMO/CMO. Develop the drugs substances in advance and involve the International new drugs R&D.

Future Outlook (2/2)


P4 & P3 Products (5-10 years launch)

- CKD-Associated Pruritus
  Difelikefalin Acetate
- Multiple Sclerosis
  Ozanimod HCl
- Genetic Obesity
  Setmelanotide Acetate
- SCLC Myelopreservation Therapy
  Trilaciclib 2HCl
- Diabetes,Type2, Cardiovascular Risk Reduction, Weight Loss
  Semaglutide

P3 Products (3-5 years launch)

- Epilepsy, Seizures
  Eslicarbazepine Acetate, Brivaracetam
- Neurofibromatosis Type 1
  Selumetinib Sulfate
- Hematology
  Eltrombopag Olamine
- Breast Cancer
  Palbociclib, Ribociclib Succinate
- Rheumatoid Arthritis
  Baricitinib, Tofacitinib Citrate

◆ **Development Milestones**



List of Abbreviations

Abbreviation	Full name	Treatment for
EPAE	Ethyl Icosapentate	Hypertriglyceridemia, Cardiovascular Risk Reduction
EVE	Everolimus	Renal Cell Carcinoma, Breast Cancer, Neuroendocrine Carcinoma Organ Transplant, Rejection Prophylaxis
FK506	Tacrolimus	Organ Transplant, Rejection Prophylaxis
MMF	Mycophenolate Mofetil	Organ Transplant, Rejection Prophylaxis
RAPA	Rapamycin (Sirolimus)	Immunosuppressant
CAS	Caspofungin Acetate	Antifungal
DFK	Difelikefalin acetate	Chronic Kidney Disease-Associated Pruritus

Always a Team Player







http://www.ccsb.com.tw

Stock Code：1762